Palvella Set to Unveil Phase 3 Results for Rare Disease Drug QTORIN
Event summary
- Palvella Therapeutics will announce topline Phase 3 SELVA trial results for QTORIN™ rapamycin in microcystic lymphatic malformations on February 24, 2026.
- Conference call scheduled for 8:00 AM ET, with a press release expected at 6:30 AM ET the same day.
- QTORIN™ rapamycin is an investigational topical treatment for rare vascular malformations with no FDA-approved therapies currently available.
The big picture
Palvella's Phase 3 results could validate the use of topical rapamycin in rare vascular malformations, an area with significant unmet medical need. The outcome will be critical for Palvella’s strategic pivot toward commercializing orphan drugs, following a series of setbacks in broader dermatology indications.
What we're watching
- Regulatory Pathway
- Whether the Phase 3 results will position QTORIN™ rapamycin for a potential FDA approval submission.
- Commercial Strategy
- How Palvella plans to commercialize QTORIN™ if approved, given the niche nature of microcystic lymphatic malformations.
- Pipeline Progress
- The pace at which Palvella advances its second product candidate, QTORIN™ pitavastatin, for disseminated superficial actinic porokeratosis.
Related topics